COVID-19 - March 23, 2021
NIAID statement on AZD1222 US Phase III trial data
Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial. The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the […]
COVID-19 - September 1, 2020
AstraZeneca expands its US COVID-19 vaccine trial
Development of AstraZeneca’s COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups. The US trial, called D8110C00001, is funded by the Biomedical Advanced Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) […]